Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein.
A novel series of substituted N-benzyl-N-phenyl-trifluoro-3-amino-2-propanols are described that reversibly inhibit cholesteryl ester transfer protein (CETP). Starting with screening lead 22, various structural features were explored with respect to inhibition of the CETP-mediated transfer of [(3)H]cholesterol from high-density cholesterol donor particles to low-density cholesterol acceptor particles. The free hydroxyl group of the propanol was required for high potency, since acylation or alkylation reduced activity. High inhibitory potency was also associated with 3-ether moieties in the aniline ring, and the highest potencies were exhibited by 3-phenoxyaniline analogues. Activity was substantially reduced by oxidation or substitution in the methylene of the benzylic group, implying that the benzyl ring orientation was important for activity. In the benzylic group, substitution at the 3-position was preferred over either the 2- or the 4-positions. Highest potencies were observed with inhibitors in which the 3-benzylic substituent had the potential to adopt an out of plane orientation with respect to the phenyl ring. The best 3-benzylic substituents were OCF(2)CF(2)H (42, IC(50) 0.14 microM in buffer, 5.6 microM in human serum), cyclopentyl (39), 3-iso-propoxy (27), SCF(3) (67), and C(CF(3))(2)OH (36). Separation of 42 into its enantiomers unexpectedly showed that the minor R(+) enantiomer 1a was 40-fold more potent (IC(50) 0.02 microM in buffer, 0.6 microM in human serum) than the major S(-) enantiomer 1b, demonstrating that the R-chirality at the propanol 2-position is key to high potency in this series. The R(+) enantiomer 1a represents the first reported acyclic CETP inhibitor with submicromolar potency in plasma. A chiral synthesis of 1a is reported.
Pharmacia Discovery Research, 700 Chesterfield Parkway North, St. Louis, Missouri 63198, USA. richard.c.durley@pharmacia.com
Richard C
RC
Durley
Margaret L
ML
Grapperhaus
Brian S
BS
Hickory
Mark A
MA
Massa
Jane L
JL
Wang
Dale P
DP
Spangler
Deborah A
DA
Mischke
Barry L
BL
Parnas
Yvette M
YM
Fobian
Nigam P
NP
Rath
Dorothy D
DD
Honda
Ming
M
Zeng
Daniel T
DT
Connolly
Deborah M
DM
Heuvelman
Bryan J
BJ
Witherbee
Michele A
MA
Melton
Kevin C
KC
Glenn
Elaine S
ES
Krul
Mark E
ME
Smith
James A
JA
Sikorski
D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D002352:Carrier Proteins / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D053480:Cholesterol Ester Transfer Proteins; D020650:Combinatorial Chemistry Techniques; D006224:Cricetinae; D018360:Crystallography, X-Ray; D006023:Glycoproteins; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008647:Mesocricetus; D051379:Mice; D008810:Mice, Inbred C57BL; D008958:Models, Molecular; D015394:Molecular Structure; D010647:Phenyl Ethers / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D011412:Propanolamines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
C465459:3-((3-phenoxyphenyl)((3-(1,1,2,2-tetrafluoroethoxy)phenyl)methyl)amino)-1,1,1-trifluoro-2-propanol; D000814:Aniline Compounds; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010647:Phenyl Ethers; D011412:Propanolamines; D012709:Serum Albumin